Investment analysts at Wedbush began coverage on shares of Cresco Labs (OTCMKTS:CRLBF) in a research report issued on Thursday. The brokerage set an "outperform" rating on the stock.
Cresco Labs Is Leading The U.S. Cannabis Market
Other equities research analysts have also issued research reports about the stock. BTIG Research restated a "buy" rating on shares of Cresco Labs in a report on Friday, October 28th. Alliance Global Partners dropped their target price on Cresco Labs from C$15.00 to C$10.00 in a research report on Wednesday, August 17th. Piper Sandler reduced their price target on Cresco Labs from $9.00 to $6.00 and set an "overweight" rating on the stock in a report on Thursday, August 18th. Cantor Fitzgerald decreased their price target on Cresco Labs from $19.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, August 18th. Finally, Canaccord Genuity Group cut their price objective on Cresco Labs from C$9.50 to C$8.00 in a research report on Thursday, August 18th. Seven equities research analysts have rated the stock with a buy rating.